Amazing congress in Milan! Superhost Giuseppe Lo Russo #lungcancer cocktail with science

Don't forget ICI dark side!! 🌚 56 RCTs, 14 cancers, 40.125 subjects: Early mortality upon 1st line ICI occurs in 14% of pts, mainly in gastric and urothelial cancers and regardless of PD-L1. Combination treatments: the way to halve early deaths. giuseppe viscardi authors.elsevier.com/a/1g2lD3QE--RX…

Save the date: AI for Oncology on May 5 at Istituto Tumori in presence Milan Italy! High-profile speakers from across the world will demonstrate it’s not just a trendy topic but one that will be part of our work. #AI #cancer (free registration) @ events-communication.com/event/ai

The #STYLE trial, which aimed to evaluate activity and safety of #sunitinib in advanced/recurrent type B3 #thymoma and #thymiccarcinoma (TC), confirms the activity of sunitinib in TC patients supporting its use as a second line treatment: bit.ly/467hgcS #LCSM

💫 Between myth and reality! #NSCLC Dr. Martina Imbimbo's (Martina Imbimbo) team at CHUV / Centre hospitalier universitaire vaudois #review the current state and modalities of adoptive #CellTherapy (ACT) in non-small cell lung carcinoma. 🔗 bit.ly/45PVVUh

🚨Cellular therapies and lung cancer. Where are we? What's new? Hope or hype? Alex Friedlaender Read our review to find out 👇👇👇👇 rdcu.be/dkOf2

Want to be update on the state-of-art for treatment for Lung Cancer, and much more? Join in person or online, terrific faculty! lungcancer-milan.com Giuseppe Lo Russo Congress is in English!

Super !!! arsela prelaj knowledge, innovation and a big <3

Results from RELEVENT trial confirm the role of antiangionetic in TC. The best first plus chemo: ORR 80%, DCR 100%, PFS 18mo and OS 43mo. Good safety profile. 💥💥💥 Istituto Tumori and TYME network #ESMO23

So proud to see the amazing results of this Italian collaborative effort (Tyme network) at ESMO 23. A big step ahead for patients affected by this rare cancer

Terrific congress, so honored to be in the faculty and share the session with 2 giants. Thanks to organizers for the comprehensive program, outstanding faculty and focus on translation research #IO23 IASLC Roberto Ferrara

Artificial (and w-human) intelligence at service of immunooncology arsela prelaj #IO23 driving innovation Roberto Ferrara IASLC

Just out ph2 MEDIOLA trial Toward a chemo free regimen for women affected by ovarian cancer? 👇👇 - Olaparib + durva ➡️ notable activity in women with gBRCAm PSROC - Olaparib + durva + beva ➡️ encouraging activity in women with non-gBRCAm PSROC aacrjournals.org/clincancerres/…

AI will be more and more a tool for today's and tomorrow's oncologists. Don't miss this opportunity to showcase your work and connect with great faculty! #AIisthenewstethoscope(cit.)

So cool! Cochrane lung cancer group !

Such a delicate and important matter. Much to do and more to come! #FlorezLab Fedro Peccatori MD, PhD

Congratulations G Curigliano MD PhD! Very well deserved! The best is yet to come! ESMO - Eur. Oncology

I'm full of joy for having been interviewed by my friend and greatest scientist Khalid El Bairi for the The ASCO Post ! #Globaloncology #ONCOLLEGE #cancer 🗺️

Don’t miss the V edition of the #CocktailWithScience #LungCancer meeting in Milan🫁 👉🏻 lungcancer-milan.com Hosted by Giuseppe Lo Russo with a world-class faculty